cancer Archives -

It has suspected for many years that some diseases may be linked to non-coding or ‘junk’ DNA, but

UK scientists say they have found cancer driver in junk DNA

https://pharmaphorum.com/news/uk-scientists-say-they-have-found-cancer-driver-in-junk-dna/

Events/ Events/ Oncology

2nd NSCLC Drug Development Summit

jade faulkner cancer, lung cancer, NSCLC, NSCLC drug development, Oncology 0 Comment

Transforming NSCLC standards of care

2nd NSCLC Drug Development Summit

https://pharmaphorum.com/events/2nd-nsclc-drug-development-summit/

Events/ Events/ Oncology

4th RAS-Targeted Drug Development Summit

Erin Thomas cancer, Oncology, pharma, R&D, RAS 0 Comment

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible.

4th RAS-Targeted Drug Development Summit

https://pharmaphorum.com/events/4th-ras-targeted-drug-development-summit/

Events/ Events/ Oncology

Targeted Radiopharmaceuticals Summit US (TRP US)

Erin Thomas cancer, Oncology, radioligand, Radiopharmaceutical, radiotherapy 0 Comment

The inaugural Targeted Radiopharmaceuticals Summit US will bring together a worldwide community of specialists to address long-standing challenges in radiopharmaceutical

Targeted Radiopharmaceuticals Summit US (TRP US)

https://pharmaphorum.com/events/targeted-radiopharmaceuticals-summit-us-trp-us/

Advancing Engineered, Native & Bispecific TCRs to Effectively Treat Solid Tumors

Events/ Events/ Oncology

TCR-based Therapeutics for Solid Tumors Summit

Rhianna Price cancer, Oncology, R&D, solid tumor, TCR 0 Comment

Hear from experts at the TCR based Therapeutics Summit

TCR-based Therapeutics for Solid Tumors Summit

https://pharmaphorum.com/events/tcr-based-therapeutics-for-solid-tumors-summit/

Events/ Events/ Oncology

Welcome to the 2nd Tumor Myeloid-Directed Therapies Summit

Hollie Bulfin cancer, immuno-oncology, myeloid biology, Oncology, tumor microenvironment 0 Comment

Identify, Validate, & Clinically Develop Novel Targets to Modulate Myeloid Cells & Overcome Solid Tumor Barriers Returning in

Welcome to the 2nd Tumor Myeloid-Directed Therapies Summit

https://pharmaphorum.com/events/welcome-to-the-2nd-tumor-myeloid-directed-therapies-summit/

Market Access/ News/ News

Biliary tract cancer drug granted orphan drug designation in US

Joy Persaud cancer, fda, market access, pharma, R&D 0 Comment

The US regulator has granted biliary tract cancer therapy Silmitasertib orphan drug designation. There are currently no treatments

Biliary tract cancer drug granted orphan drug designation in US

https://pharmaphorum.com/news/biliary-tract-cancer-drug-granted-orphan-drug-designation-in-us/

News/ News/ Oncology

Sugemalimab plus chemo boosts lung cancer survival, trial reveals

Joy Persaud cancer, clinical trials, lung cancer, pharma 0 Comment

Lung cancer drug sugemalimab has delivered positive results following a phase 3 trial. The GEMSTONE-302 study evaluated the

Sugemalimab plus chemo boosts lung cancer survival, trial reveals

https://pharmaphorum.com/news/sugemalimab-plus-chemo-boosts-lung-cancer-survival-trial-reveals/

News/ News/ Oncology

Clinical trial begins of lung cancer immunotherapeutic

Jonah Comstock cancer, Cancer Research UK, clinical trials, Oncology, R&D 0 Comment

Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has

Clinical trial begins of lung cancer immunotherapeutic

https://pharmaphorum.com/news/clinical-trial-begins-of-lung-cancer-immunotherapeutic/

Trending

cancer

Login